Why 2017 Could Be This Stock's Best Year Yet
Nearly five years ago, Abbott Labs spun off its biopharmaceutical unit into a separate entity. That new company, AbbVie (NYSE: ABBV), enjoyed a tremendous first year, with its share price soaring more than 50% in 2013. However, the following years weren't as great for AbbVie. Until now.
Granted, AbbVie stock isn't up more than 50% year to date at this point. But it's really close to that level. And there's plenty of time remaining in the year. Here's why 2017 could be the stocks's best year yet.
Image source: Getty Images.
Source: Fool.com